Pentagon Pushes Testosterone Testing, Raising Concerns Over Military Priorities and Social Engineering
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
The Defense Department will test troops for low testosterone and offer hormone therapy, citing readiness. Critics question the scientific basis and warn of further politicization and gender ideology in the military.
The Pentagon announced it will begin testing active-duty troops for low testosterone levels and, if deemed necessary, provide hormone replacement therapy. Officials claim the measure is meant to keep service members 'strong, resilient and capable' and to support 'maximum psychological and mental readiness' on the battlefield. However, many see this as another example of the military’s increasing focus on social engineering at the expense of traditional standards.
This policy follows a 2022 incident in which a Navy SEAL recruit died during training and was found with testosterone and other substances in his system. The Navy responded by starting a drug-testing program for hormonal agents that promote muscle growth. Now, Defense Secretary Mike Hegseth is expanding this approach, insisting the new initiative is not for 'artificial enhancement.'
Despite the sweeping nature of the policy, the Department of Defense has not provided details on the research or clinical guidelines informing the program. There is also no clarity on whether female personnel will be evaluated for estrogen-based therapy during perimenopause, raising concerns about the growing influence of gender ideology and the push for so-called 'equity' in the ranks.
Medical experts note that testosterone naturally declines with age and can be linked to symptoms such as low libido, mood changes, and weight gain. Current guidelines recommend testing only men with relevant symptoms and confirmed low levels on two separate morning blood draws. The FDA has recently loosened prescribing limits for testosterone products, but the label still restricts use to men with hypogonadism, reflecting the need for caution and medical oversight.
Republican Representative Chrissy Houlahan, a Pennsylvania Air Force veteran, sharply criticized the announcement, arguing it reflects the influence of fringe online groups and demanding that any testing be made available to both men and women. Her comments highlight the ongoing politicization of military health policy and the risk of undermining readiness with unproven and ideologically driven programs.
This move comes as the Pentagon has also repealed the military flu-vaccine mandate earlier this year, further demonstrating the shifting priorities and the growing influence of progressive agendas within the armed forces.